AstraZeneca (AZN) and Daiichi Sankyo's datopotamab deruxtecan, or datroway, has received approval from the US Food and Drug Administration to treat breast cancer patients who have already undergone endocrine-based therapy and chemotherapy.
The approval is based on the results of the Tropion-Breast01 phase 3 trial, which showed a 37% reduction in the risk of disease progression or death, compared with chemotherapy, and a median progression-free survival of 6.9 months versus 4.9 months with chemotherapy, AstraZeneca said in a regulatory filing Monday.
The safety profile of datroway was in line with its known characteristics, with no new safety issues identified, the company added.
Shares of AstraZeneca were up 1.9% in recent Tuesday trading.
Price: 67.85, Change: +1.25, Percent Change: +1.88
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.